Prostatype Genomics

01/08/2026

Nature published new U.S. peer-reviewed data validating the Prostatype® P-score for prostate cancer risk stratification at diagnosis. In a multiethnic VA cohort, Prostatype predicted prostate cancer–specific mortality with a c-index of 0.87, outperforming PSA, grade, and NCCN risk group, with robust performance in intermediate-risk patients. Over 70% African American, addressing a major validation gap.

Across prior validations, the Prostatype P-score has also shown:
• 10-year metastasis prediction with AUCs in the ~0.88 range
• Adverse pathology prediction at prostatectomy with AUCs ~0.81
• Consistent performance across demographically diverse populations in 5 countries and 3 continents.
• Long term prediction with 25-year data presented at AUA 2024 demonstrating the Prostatype® P-score stratified biochemical recurrence and prostate cancer–specific mortality—with no prostate cancer deaths in the low- or intermediate-risk groups supporting superior biologic risk stratification.
Collectively, these data support Prostatype as a clinically meaningful genomic classifier to help reduce both undertreatment of aggressive disease and overtreatment of indolent prostate cancer at the point of diagnosis.

The Prostatype® Test evaluates expression levels of three stem cell genes (IGFBP3, F3, and VGLL3), which are combined with PSA, stage, and grade to calculate P-score. Previous research found P-score accurately predicts prostate cancer (PC) specific mortality (PCSM) in patients with newly diagnosed ...

04/23/2025

Prostate cancer affects approximately 1.3 million men annually worldwide. Our test provides a comprehensive assessment of prostate cancer aggressiveness by analyzing tissue from the diagnostic biopsy — meaning no additional sampling is required.

By combining gene expression information from three cancer stem cell genes with the clinical parameters (PSA, Gleason Score and Tumor Stage), we calculate the patient’s risk for 10yr PCS, 10yr Mets and Ap at RP.

04/15/2025

Our new website is live!

At Prostatype Genomics, we’re transforming prostate cancer care through innovative genetic testing. Visit our new website to learn how the Prostatype Genomic Classifier is helping doctors and patients make more confident treatment decisions.
https://prostatype.com/

04/09/2025

Using clinical parameters alone many prostate cancer patients may not receive the immediate care they need or undergo treatments they don’t need? We’re working to change that through advanced genomic testing. Visit our booth 924 in Las Vegas (April 26-29) to learn how our test helps clinicians make informed treatment decisions based on each patient’s genetic profile and a binary test result.

04/03/2025

Stop by our booth 924 to learn how the Prostatype Genomic Classifier is changing the landscape of prostate cancer management. Our test helps stratify prostate cancer patients with a high/low risk binary test result, potentially reducing unnecessary treatments while ensuring high-risk patients receive appropriate care.

03/28/2025

Our CEO, Fredrik Rickman, will speak at the Innovation Track at the CAGLA NeauxCancer Conference hosted by the Cancer Advocacy Group of Louisiana on March 29th at 8:30 a.m. in New Orleans.

More than 1.3 million men are diagnosed with prostate cancer annually worldwide. Mr. Rickman will discuss how our test combines three stem cell gene predictor with clinical parameters to create a dichotomized result, which indicates prostate cancer specific mortality risk in prostate cancer patients. This helps clinicians identify who needs aggressive treatment versus active surveillance, potentially saving lives and improving quality of life.

Mr. Rickman will also be available for one-on-one meetings with investors throughout the conference. If you’re an investor who believes in the future of personalized prostate cancer care, this is a presentation you don’t want to miss!
For the remote livestream of the presentation please use the following. https://bit.ly/4j0cDac